A recent study reveals that individuals who stop using popular weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who stop traditional diet and exercise programs.
Findings released in a prominent health publication demonstrates that while overweight individuals can lose substantial amounts of their body weight while on the medication, the weight is regained at an average rate of 0.8 kg per month after stopping.
"Users using such treatments should be aware of the danger of rapid rebound weight gain when the medication is stopped," warns researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment weight within about one and a half years.
Weighing Approaches
The analysis, which reviewed dozens of trials involving over 9,000 of patients, compared the results of these new drugs with other pills.
The team emphasize that people who shed pounds through lifestyle changes alone typically experience a more gradual weight regain—around 0.1 kg a month—after stopping.
Understanding the Fast Rebound
Doctors suggest the mechanism of the injections explains the heightened rebound.
These medications copy a natural hormone called GLP-1, which controls hunger.
"Long-term administration of GLP-1 levels several times higher than normal may cause the body to generate a reduced amount of its endogenous GLP-1, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement leads to appetite is no longer kept in check, making excessive eating far more likely."
An Ongoing Condition?
Health authorities recommend the jabs for individuals with obesity-related health risks, alongside recommended lifestyle changes.
Many experts say that, considering the high risk of relapse, the therapy is often ongoing.
This opinion is supported by drug manufacturers, who note that the results "highlight the long-term nature of obesity," comparing it to managing conditions like hypertension.
Patient Experiences
People who have come off the medication describe a sudden return of cravings.
"I experienced a trigger activating and you become ravenous," described a patient.
This difficulty is compounded if users have not adopted lasting dietary or behavioural changes during therapy.
Widespread Interest
Recent estimates show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Use is higher among women compared to males.
- The middle-aged age group shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than public health services.
In conclusion, clinicians caution that while these medications are powerful agents for weight loss, they are not a permanent solution and long-term success relies on combined behavioural management.
